Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis

Oncogene

Volumn 31, Issue 30, 2012, Pages 3516-3524

  Gillibert Duplantier, J ^a,b,c   Duthey, B ^a,b,c   Sisirak, V ^d,e,f   Salaun D ^a,b,c   Gargi, T ^e   Tredan O ^e   Finetti, P ^a,b   Bertucci, F ^a,b,c   Birnbaum, D ^a,b,c   Bendriss Vermare, N ^d,e,f   Badache, A ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e CENTRE LÉON BÉRARD   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

cell migration; ErbB2 Her2; metastasis; ST2 IL1RL1; transcriptome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 1 RECEPTOR LIKE 1; PROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTIBODIES, BLOCKING; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84864368589     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.525     Document Type: Article

References (47)

1. Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M et al. (2005). FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 171: 505-516. (Pubitemid 41586939)
2. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. (1994). Alternative promoter usage of the Fos-responsive gene FiT-1 generates mRNA isoforms coding for either secreted or membranebound proteins Related to the IL-1 receptor. EMBO J 13: 1176-1188. (Pubitemid 24074724)
3. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357. (Pubitemid 43128862)
4. Bosc DG, Goueli BS, Janknecht R. (2001). HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 20: 6215-6224. (Pubitemid 32964434)
5. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E et al. (2004). Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 30: 1468-1473. (Pubitemid 38951733)
6. Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F et al. (2006). Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol 169: 268-278.
7. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N et al. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284.
8. Dankort D, MaslikowsKi B, Warner N, Kanno N, Kim H, Wang Z et al. (2001). Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol 21: 1540-1551. (Pubitemid 32156374)
9. Dufour A, Sampson NS, Zucker S, Cao J. (2008). Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 217: 643-651.
10. Eisen MB, Spellman PT, Brown PO, Botstein D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868. (Pubitemid 29003722)
11. Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G et al. (2002). Prominent role of the Ig-like V domain in trans-inteRactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C'-D beta-strands of the nectin1V domain. J Biol Chem 277: 27006-27013. (Pubitemid 34951712)
12. Gayle MA, Slack JL, Bonnert TP, Renshaw BR, Sonoda G, Taguchi T et al. (1996). Cloning of a putative ligand for the T1/ST2 receptor. J Biol Chem 271: 5784-5789. (Pubitemid 26083917)
13. Grossmann KS, Wende H, Paul FE, Cheret C, Garratt AN, Zurborg S et al. (2009). The tyrosine phosphatase Shp2 (PTPN11) directs neuregulin-1/ErbB signaling throughout Schwann cell development. Proc Natl Acad Sci USA 106: 16704-16709.
14. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582.
15. Hayakawa H, Hayakawa M, Kume A, Tominaga S. (2007). Soluble ST2 blocks interleuKin-33 signaling in allergic airway iNFlammation. J Biol Chem 282: 26369-26380. (Pubitemid 47443815)
16. Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D et al. (2000). Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int J Oncol 17: 629-641.
17. Ho IA, Chan KY, Ng WH, Guo CM, Hui KM, Cheang P et al. (2009). Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27: 1366-1375.
18. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
19. Jarry A, Dorso L, Gratio V, Forgue-Lafitte ME, Laburthe M, Laboisse CL et al. (2007). PAR-2 activation increases human intestinal mucin secretion through EGFR transactivation. Biochem Biophys Res Commun 364: 689-694. (Pubitemid 350030925)
20. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. (2002). The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4: 540-544. (Pubitemid 34752442)
21. Kakkar R, Lee RT. (2008). The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7: 827-840.
22. Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL et al. (2009). ErbB1 and ErbB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res 15: 3733-3739.
23. Klemenz R, Hoffmann S, WerensKiold AK. (1989). Serum-and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA 86: 5708-5712. (Pubitemid 19217524)
24. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E et al. (1998). Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18: 7095-7105. (Pubitemid 28533029)
25. Marone R, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A. (2004). Memo mediates ErbB2-driven cell motility. Nat Cell Biol 6: 515-522. (Pubitemid 38786594)
26. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firsT-line TREatment: the M77001 study group. J Clin Oncol 23: 4265-4274. (Pubitemid 46207001)
27. Mazumdar A, Adam L, Boyd D, Kumar R. (2001). Heregulin regulation of uroKinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res 61: 400-405. (Pubitemid 32095743)
28. Meisel C, Bonhagen K, Lohning M, Coyle AJ, Gutierrez-Ramos JC, Radbruch A et al. (2001). Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytoKine production by T1/ST2 cross-linKing. J Immunol 166: 3143-3150. (Pubitemid 33117311)
29. Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R et al. (2005). CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7: 521-532. (Pubitemid 40799246)
30. Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, TREjo J. (2006). Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 66: 307-314. (Pubitemid 43166037)
31. Olayioye MA, Neve RM, Lane HA, Hynes NE. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19: 3159-3167. (Pubitemid 30428195)
32. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S et al. (2001). Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 164: 277-281. (Pubitemid 34001295)
33. Rossler U, Thomassen E, Hultner L, Baier S, Danescu J, WerensKiold AK. (1995). Secreted and membrane-Bound isoforms of T1, an orphan receptor Related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 168: 86-97.
34. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117: 1538-1549. (Pubitemid 46871338)
35. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. (2005). IL-33, an interleuKin-1-like cytoKine that signals via the IL-1 receptor-Related protein ST2 and induces T helper type 2-associated cytoKines. Immunity 23: 479-490. (Pubitemid 41587888)
36. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: corRelation of Relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
37. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712. (Pubitemid 19147683)
38. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. (Pubitemid 32222155)
39. Spencer KS, Graus-Porta D, Leng J, Hynes NE, Klemke RL. (2000). ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine Kinases. J Cell Biol 148: 385-397. (Pubitemid 30078250)
40. Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN et al. (2009). Proteinaseactivated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene 28: 3047-3057.
41. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. (2003). The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 124: 1206-1214. (Pubitemid 37290028)
42. Tominaga S. (1989). A putative protein of a growth specific CDNA from BALB/c-3T3 cells is highly similar to the extRacellular portion of mouse interleuKin 1 receptor. FEBS Lett 258: 301-304. (Pubitemid 20001074)
43. Tominaga S, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N. (1999). Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 264: 14-18. (Pubitemid 29500455)
44. Vial E, Sahai E, Marshall CJ. (2003). ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4: 67-79. (Pubitemid 36904162)
45. WerensKiold AK, Hoffmann S, Klemenz R. (1989). Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol 9: 5207-5214. (Pubitemid 19275992)
46. Yarden Y, SliwkowsKi MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137. (Pubitemid 33674041)
47. Zaoui K, Honore S, Isnardon D, Braguer D, Badache A. (2008).Memo-RhoA- mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells. J Cell Biol 183: 401-408.